全文获取类型
收费全文 | 494264篇 |
免费 | 56076篇 |
国内免费 | 756篇 |
出版年
2018年 | 4801篇 |
2017年 | 4584篇 |
2016年 | 6710篇 |
2015年 | 9885篇 |
2014年 | 11466篇 |
2013年 | 15472篇 |
2012年 | 18509篇 |
2011年 | 18988篇 |
2010年 | 12605篇 |
2009年 | 11492篇 |
2008年 | 16622篇 |
2007年 | 17270篇 |
2006年 | 16304篇 |
2005年 | 15494篇 |
2004年 | 15591篇 |
2003年 | 14641篇 |
2002年 | 14101篇 |
2001年 | 19424篇 |
2000年 | 19206篇 |
1999年 | 15526篇 |
1998年 | 6092篇 |
1997年 | 5882篇 |
1996年 | 5563篇 |
1995年 | 5625篇 |
1994年 | 5310篇 |
1993年 | 5339篇 |
1992年 | 12920篇 |
1991年 | 12805篇 |
1990年 | 12572篇 |
1989年 | 12025篇 |
1988年 | 11202篇 |
1987年 | 10568篇 |
1986年 | 10096篇 |
1985年 | 9919篇 |
1984年 | 8415篇 |
1983年 | 7293篇 |
1982年 | 5711篇 |
1981年 | 5248篇 |
1980年 | 4904篇 |
1979年 | 7690篇 |
1978年 | 6355篇 |
1977年 | 5674篇 |
1976年 | 5296篇 |
1975年 | 6054篇 |
1974年 | 6635篇 |
1973年 | 6415篇 |
1972年 | 5660篇 |
1971年 | 5248篇 |
1970年 | 4477篇 |
1969年 | 4389篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
1.
2.
3.
Michael P. Gustafson Yi Lin Mary L. Maas Virginia P. Van Keulen Patrick B. Johnston Tobias Peikert Dennis A. Gastineau Allan B. Dietz 《PloS one》2015,10(3)
The development of flow cytometric biomarkers in human studies and clinical trials has been slowed by inconsistent sample processing, use of cell surface markers, and reporting of immunophenotypes. Additionally, the function(s) of distinct cell types as biomarkers cannot be accurately defined without the proper identification of homogeneous populations. As such, we developed a method for the identification and analysis of human leukocyte populations by the use of eight 10-color flow cytometric protocols in combination with novel software analyses. This method utilizes un-manipulated biological sample preparation that allows for the direct quantitation of leukocytes and non-overlapping immunophenotypes. We specifically designed myeloid protocols that enable us to define distinct phenotypes that include mature monocytes, granulocytes, circulating dendritic cells, immature myeloid cells, and myeloid derived suppressor cells (MDSCs). We also identified CD123 as an additional distinguishing marker for the phenotypic characterization of immature LIN-CD33+HLA-DR- MDSCs. Our approach permits the comprehensive analysis of all peripheral blood leukocytes and yields data that is highly amenable for standardization across inter-laboratory comparisons for human studies. 相似文献
4.
Aruna S. Jaiswal Harekrushna Panda Brian K. Law Jay Sharma Jitesh Jani Robert Hromas Satya Narayan 《PloS one》2015,10(5)
Recently approved chemotherapeutic agents to treat colorectal cancer (CRC) have made some impact; however, there is an urgent need for newer targeted agents and strategies to circumvent CRC growth and metastasis. CRC frequently exhibits natural resistance to chemotherapy and those who do respond initially later acquire drug resistance. A mechanism to potentially sensitize CRC cells is by blocking the DNA polymerase β (Pol-β) activity. Temozolomide (TMZ), an alkylating agent, and other DNA-interacting agents exert DNA damage primarily repaired by a Pol-β-directed base excision repair (BER) pathway. In previous studies, we used structure-based molecular docking of Pol-β and identified a potent small molecule inhibitor (NSC666715). In the present study, we have determined the mechanism by which NSC666715 and its analogs block Fen1-induced strand-displacement activity of Pol-β-directed LP-BER, cause apurinic/apyrimidinic (AP) site accumulation and induce S-phase cell cycle arrest. Induction of S-phase cell cycle arrest leads to senescence and apoptosis of CRC cells through the p53/p21 pathway. Our initial findings also show a 10-fold reduction of the IC50 of TMZ when combined with NSC666715. These results provide a guide for the development of a target-defined strategy for CRC chemotherapy that will be based on the mechanisms of action of NSC666715 and TMZ. This combination strategy can be used as a framework to further reduce the TMZ dosages and resistance in CRC patients. 相似文献
5.
Tom P. Moorhouse Cecilia A. L. Dahlsj? Sandra E. Baker Neil C. D'Cruze David W. Macdonald 《PloS one》2015,10(10)
Tourism accounts for 9% of global GDP and comprises 1.1 billion tourist arrivals per annum. Visits to wildlife tourist attractions (WTAs) may account for 20–40% of global tourism, but no studies have audited the diversity of WTAs and their impacts on the conservation status and welfare of subject animals. We scored these impacts for 24 types of WTA, visited by 3.6–6 million tourists per year, and compared our scores to tourists’ feedback on TripAdvisor. Six WTA types (impacting 1,500–13,000 individual animals) had net positive conservation/welfare impacts, but 14 (120,000–340,000 individuals) had negative conservation impacts and 18 (230,000–550,000 individuals) had negative welfare impacts. Despite these figures only 7.8% of all tourist feedback on these WTAs was negative due to conservation/welfare concerns. We demonstrate that WTAs have substantial negative effects that are unrecognised by the majority of tourists, suggesting an urgent need for tourist education and regulation of WTAs worldwide. 相似文献
6.
7.
8.
9.
10.